title: Both carvedilol and nebivolol may improve platelet function and prothrombotic state in patients with nonischemic heart failure.
abstract: It is unclear whether carvedilol and nebivolol will produce different effects on platelet function and prothrombotic state in heart failure (HF). Thus, we compared their effects on these functions in patients with nonischemic HF. We included 61 patients with symptomatic nonischemic HF having ejection fraction ≤40%. The patients were randomized to carvedilol (n = 31) or nebivolol (n = 30). Analyses were made at baseline, 3, and 6 months. At 6 months, mean platelet volume (MPV) was significantly lowered by both carvedilol and nebivolol therapy. However, MPV tended to be lower in the carvedilol group (7.7 ± 1.0 vs 8.0 ± 0.7 fL, P = .05). Fibrinogen and d-dimer levels were significantly decreased in but comparable in both the groups. Carvedilol and nebivolol have similar beneficial effects on platelet function and prothrombotic state in patients with nonischemic HF.
authors.affiliation: Department of Cardiology, Isparta State Hospital, Isparta, Turkey drmustafa1979@hotmail.com.
authors.forename: Mustafa
authors.initials: M
authors.lastname: Karabacak
authors.affiliation: Department of Cardiology, Medical Faculty, Suleyman Demirel University, Isparta, Turkey.
authors.forename: Abdullah
authors.initials: A
authors.lastname: Dogan
authors.affiliation: Suleyman Demirel University, Isparta, Turkey.
authors.forename: Fatih
authors.initials: F
authors.lastname: Aksoy
authors.affiliation: Department of Cardiology, Medical Faculty, Suleyman Demirel University, Isparta, Turkey.
authors.forename: Mehmet
authors.initials: M
authors.lastname: Ozaydin
authors.affiliation: Department of Cardiology, Medical Faculty, Suleyman Demirel University, Isparta, Turkey.
authors.forename: Dogan
authors.initials: D
authors.lastname: Erdogan
authors.affiliation: Suleyman Demirel University, Isparta, Turkey.
authors.forename: Pinar
authors.initials: P
authors.lastname: Karabacak
mesh_terms: D058671:Adrenergic beta-1 Receptor Antagonists / Q000627:therapeutic use*; D001578:Benzopyrans / Q000627:therapeutic use*; D002227:Carbazoles / Q000627:therapeutic use*; D000077261:Carvedilol; D004359:Drug Therapy, Combination; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male; D063847:Mean Platelet Volume; D008875:Middle Aged; D000068577:Nebivolol; D011412:Propanolamines / Q000627:therapeutic use*; D016037:Single-Blind Method
chemical_list: D058671:Adrenergic beta-1 Receptor Antagonists; D001578:Benzopyrans; D002227:Carbazoles; D004983:Ethanolamines; D005338:Fibrin Fibrinogen Degradation Products; D011412:Propanolamines; C036309:fibrin fragment D; D000068577:Nebivolol; D000077261:Carvedilol; D005340:Fibrinogen
keywords:     d-dimer; carvedilol; fibrinogen; heart failure; mean platelet volume; nebivolol